Positive/JJ
and/CC
negative/JJ
regulation/NN
of/IN
the/DT
composite/JJ
octamer/NN
motif/NN
of/IN
the/DT
interleukin/NN
2/CD
enhancer/NN
by/IN
AP-1/NN
,/,
Oct-2/NN
,/,
and/CC
retinoic/JJ
acid/NN
receptor/NN
./.

The/DT
differentiating/VBG
agent/NN
retinoic/JJ
acid/NN
(/(
RA/NN
)/)
has/VBZ
been/VBN
previously/RB
reported/VBN
to/TO
interfere/VB
with/IN
12-O-tetradecanoyl-phorbol-13-acetate/NN
(/(
TPA/NN
)/)
/Ca(2+)-induced/JJ
signals/NNS
for/IN
the/DT
regulation/NN
of/IN
the/DT
-96/CD
to/TO
-66-bp/JJ
octamer/NN
motif/NN
found/VBN
in/IN
the/DT
enhancer/NN
for/IN
the/DT
interleukin/NN
(/(
IL/NN
)/)
-2/CD
gene/NN
,/,
which/WDT
encodes/VBZ
a/DT
major/JJ
T/NN
lymphocyte/NN
growth/NN
factor/NN
./.
=====
The/DT
IL-2/NN
octamer/NN
motif/NN
is/VBZ
a/DT
composite/JJ
cis-element/NN
which/WDT
binds/VBZ
Oct-1/NN
and/CC
Oct-2/NN
as/RB
well/RB
as/IN
a/DT
TPA/Ca(2+)-inducible/JJ
nuclear/JJ
factor/NN
,/,
previously/RB
termed/VBN
octamer-associated/JJ
protein/NN
(/(
OAP40/CD
)/)
./.
=====
We/PRP
show/VBP
here/RB
that/IN
Oct-2/NN
,/,
despite/IN
the/DT
presence/NN
of/IN
an/DT
active/JJ
transcriptional/JJ
activation/NN
domain/NN
,/,
requires/VBZ
TPA/Ca(2+)-induced/JJ
signals/NNS
to/TO
strongly/RB
transactivate/VB
the/DT
IL-2/NN
octamer/NN
motif/NN
in/IN
Jurkat/NN
T/NN
cells/NNS
./.
=====
This/DT
Oct-2-dependent/JJ
transactivation/NN
is/VBZ
inhibited/VBN
by/IN
RA/NN
./.
=====
The/DT
presence/NN
of/IN
an/DT
intact/JJ
COOH-terminal/JJ
domain/NN
of/IN
Oct-2/NN
contributes/VBZ
to/TO
both/CC
TPA/Ca(2+)-induced/JJ
transactivation/NN
and/CC
the/DT
RA-mediated/JJ
repression/NN
./.
=====
We/PRP
also/RB
show/VBP
that/IN
both/CC
Fos/NN
and/CC
Jun/NN
components/NNS
of/IN
the/DT
AP-1/NN
factors/NNS
participate/VBP
in/IN
the/DT
OAP40/NN
complex/NN
./.
=====
Furthermore/RB
,/,
transfected/VBN
c-jun/NN
,/,
jun-B/NN
,/,
jun-D/NN
,/,
c-fos/NN
,/,
or/CC
Fos-B/NN
expression/NN
vectors/NNS
partially/RB
substitute/VBP
for/IN
TPA/NN
and/CC
Ca2+/NN
and/CC
cooperate/VBP
with/IN
Oct-2/NN
for/IN
the/DT
transactivation/NN
of/IN
the/DT
combined/JJ
OAP/octamer/NN
cis-element/NN
./.
=====
Mutations/NNS
of/IN
the/DT
genuine/JJ
octamer-binding/JJ
site/NN
abrogate/VBP
both/CC
the/DT
binding/NN
of/IN
Oct-1/NN
and/CC
Oct-2/NN
and/CC
the/DT
TPA/Ca(2+)-induced/JJ
transactivation/NN
of/IN
the/DT
OAP/octamer/NN
motif/NN
./.
=====
OAP/NN
confers/VBZ
to/TO
Oct-2/NN
responsivity/NN
to/TO
both/CC
TPA/Ca2+/NN
and/CC
RA/NN
,/,
since/IN
specific/JJ
mutations/NNS
of/IN
the/DT
AP-1/OAP-bindingsite/NN
significantly/RB
reduce/VBP
the/DT
transactivation/NN
by/IN
Oct-2/NN
in/IN
response/NN
to/TO
TPA/NN
and/CC
Ca2+/NN
and/CC
abolish/VBP
the/DT
inhibition/NN
by/IN
RA/NN
./.
=====
Furthermore/RB
,/,
retinoic/JJ
acid/NN
receptor/NN
(/(
RAR/NN
)/)
alpha/NN
is/VBZ
able/JJ
to/TO
inhibit/VB
in/FW
vitro/FW
the/DT
formation/NN
of/IN
the/DT
complex/NN
between/IN
the/DT
nuclear/JJ
AP-1/OAP/NN
and/CC
its/PRP$
specific/JJ
binding/VBG
site/NN
,/,
resulting/VBG
in/IN
the/DT
interference/NN
with/IN
Oct-2-dependent/JJ
cis-regulatory/JJ
function/NN
of/IN
this/DT
AP-1/NN
element/NN
./.
=====
Therefore/RB
,/,
we/PRP
propose/VBP
that/IN
the/DT
TPA/calcium-activatedAP-1/OAP/NN
element/NN
is/VBZ
the/DT
main/JJ
target/NN
of/IN
positive/JJ
or/CC
negative/JJ
regulatory/JJ
signals/NNS
influencing/VBG
the/DT
IL-2/NN
octamer/NN
motif/NN
,/,
through/IN
synergism/NN
with/IN
Oct-2/NN
and/CC
antagonism/NN
by/IN
RAR/NN
./.